ArticleSAGE open medical case reports2025
New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid is recognized as the most prevalent autoimmune blistering skin disease. This report presents a case of a 54-year-old male in Canada who developed new-onset bullous pemphigoid 4 weeks after receiving his fifth COVID-19 vaccine booster (Pfizer-BioNTech). The patient initially presented with a generalized erythematous rash, which progressed despite treatment with topical and systemic corticosteroids. He later developed tense blisters and peripheral eosinophilia, with a skin biopsy confirming the diagnosis of bullous pemphigoid. Although bullous pemphigoid has previously been linked to various vaccinations, the underlying mechanisms remain uncertain. Notably, cases of bullous pemphigoid flare-ups have been reported in patients with existing bullous pemphigoid after receiving mRNA COVID-19 vaccines. This report underscores the importance of considering new-onset bullous pemphigoid in patients presenting with blistering skin conditions following COVID-19 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.